Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Once-weekly islatravir + ulonivirine vs daily BIC/FTC/TAF in treatment-naïve adults with HIV-1
2025-522519-40-00Phase 3Authorised
- Sponsor
- Merck & Co.
- Start
- Feb 2026
- Modality
- Small Molecules
- Countries
- 13
01
Overview
Phase 3, randomised, double-blind trial of islatravir + ulonivirine in human immunodeficiency virus infection (HIV) (2 arms), sponsored by Merck & Co. Primary endpoints: Phase 2: Percentage of participants with HIV-1 RNA <50 copies/mL at Week 24, Phase 2: Percentage of participants who experience an adverse event (AE) at Week 24 and 4 more. Planned start Feb 2026; status: authorised.
02
Drugs
islatravir + ulonivirine
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on 2025-522519-40-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-522519-40-00.